MRS, Sectra partner to distribute MRS7 mammography tracking and reporting system

NewsGuard 100/100 Score

International medical technology company, Sectra  (NASDAQ OMX Stockholm: SECT B), announces an agreement with Mammography Reporting System Inc. (MRS), a leading mammography tracking and reporting system provider, to distribute its solution, MRS7, fully integrated with Sectra Breast Imaging PACS.  

This strategic distribution agreement and bi-directional integration with MRS7s, a widely used tracking and reporting system for all breast-related procedures, including mammography, MRI, and ultrasound, will provide Sectra customers with improved workflow efficiency.  Integrating key breast imaging tools within a single Sectra Breast Imaging PACS workstation will also allow radiologists to increase review efficiency.

Sectra's Breast Imaging PACS is a web-based, multi-modality workstation with advanced diagnostic tools that offers a powerful reading environment for high volume women's imaging centers and for those wanting to increase tele-mammography services.  All digital breast images, even breast tomosynthesis, regardless of modality vendor, are automatically displayed in the same size with correct orientation and alignment, facilitating comparison of current and prior images.  Breast imaging providers can experience increased reading efficiency by utilizing Sectra Breast Imaging PACS for all modalities.

Source:

Sectra

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New tool identifies potential breast tumors with 91% accuracy